Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

作者
Dora Niedersuess‐Beke,Karl Mayrhofer,Johanna Krauter,Johannes Franke,Dominic Vais,Maximillian Pallauf,David Kiesl,Ferdinand Luger,J. Pfuner,Angelika Terbuch,Thomas Bauernhofer,Jasmin Spielgelberg,Andreas Banner,Stefan Aufderklamm,Clemens Wiesinger,Susanne Schnabel,Simon Peter Gampenrieder,Josef Mühlmann,Sonia Vallet,Sabine Weibrecht
出处
期刊:International Journal of Cancer [Wiley]
标识
DOI:10.1002/ijc.70203
摘要

Abstract Antibody‐drug conjugates (ADCs) and immunotherapy have changed the treatment landscape for locally advanced and metastatic urothelial carcinoma (la/mUC). Clinical trials have demonstrated the superiority of enfortumab vedotin (EV) combined with pembrolizumab (P) over chemotherapy. This retrospective, multicentre Austrian registry analysis evaluated the effectiveness and safety of EV + P in treatment‐naïve la/mUC patients in a real‐world setting. This study included 203 first‐line EV + P treated patients from 20 Austrian centres. The majority were male (77.3%), with a median age of 70 years (range, 26–92), while 33.5% were ≥75 years. Comorbidities were common, with 25.1% having a Charlson Comorbidity Index (CCI) ≥ 5, and 46.3% moderate to severe renal impairment. Among 195 evaluable patients, the objective response rate (ORR) was 63.6% (95% CI, 56.6–70.0), including 21.5% complete responses and 42.1% partial responses. Disease control was achieved in 75.4% (95% CI, 68.9–80.9). Median progression‐free survival (PFS) and overall survival (OS) were not reached after a median follow‐up of 5.8 months. Poor outcomes were associated with ECOG PS >2 (PFS, p = .003; OS, p < .001) and CCI ≥5 (PFS, p = .011; OS, p = .08). EV + P was generally well tolerated; grade ≥3 treatment‐related adverse events occurred in 38.4% of patients and immune‐related adverse events in 19.2%. Limitations of this study include its retrospective design and short follow‐up. These findings support the clinical use of EV + P as first‐line treatment for la/mUC, demonstrating substantial effectiveness and manageable toxicity in a large real‐world population, including elderly and comorbid patients. Extended follow‐up is warranted to determine long‐term survival and predictive markers of response.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
乐乐的应助被liko采纳,获得10
2秒前
Maggie发布了新的文献求助10
2秒前
luoyaw完成签到 ,获得积分10
2秒前
风吹麦浪发布了新的文献求助10
2秒前
科研通AI6.3的应助被DavidChen采纳,获得10
5秒前
念旧完成签到 ,获得积分10
5秒前
正直雨完成签到,获得积分10
5秒前
哈哈完成签到,获得积分10
7秒前
灵机完成签到,获得积分10
8秒前
9秒前
10秒前
12秒前
12秒前
cdercder的应助被花渐开采纳,获得10
13秒前
稳重的冥王星完成签到,获得积分10
13秒前
刘青完成签到,获得积分10
14秒前
16秒前
liko发布了新的文献求助10
17秒前
陈鸿超发布了新的文献求助10
18秒前
JiaxinChen完成签到 ,获得积分10
18秒前
18秒前
18秒前
19秒前
小雷要学习完成签到,获得积分10
20秒前
Engen完成签到,获得积分10
22秒前
李金桥完成签到 ,获得积分10
23秒前
23秒前
很酷的妞子完成签到 ,获得积分10
23秒前
云泪天痕的应助被WGS采纳,获得10
23秒前
kuikui1100完成签到,获得积分10
24秒前
领导范儿的应助被菜鸟学习采纳,获得10
24秒前
莫远阳完成签到,获得积分10
27秒前
无聊的依白完成签到,获得积分10
28秒前
29秒前
完美世界的应助被coco采纳,获得10
29秒前
syvshc的应助被七月流火采纳,获得10
29秒前
科目三的应助被19863737023采纳,获得10
30秒前
xiao端庄完成签到,获得积分10
30秒前
32秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192871
求助须知:如何正确求助?哪些是违规求助? 9579281
关于积分的说明 21864358
捐赠科研通 7792445
什么是DOI,文献DOI怎么找? 3437059
关于科研通互助平台的介绍 2560639
邀请新用户注册赠送积分活动 2483928